Clinical Trials Logo

Refractory Tumor clinical trials

View clinical trials related to Refractory Tumor.

Filter by:

NCT ID: NCT06456138 Not yet recruiting - Clinical trials for Advanced Lung Cancer

Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC

Start date: July 1, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

Lung cancer is the most common cause of cancer-related death worldwide. Approximately 85% to 90% of lung cancer cases are non-small cell lung cancer (NSCLC), of which KRAS is one of the most common driver genes, occurring in 25-30% of lung adenocarcinomas and 3-5% of squamous cell carcinomas. KRAS-mutant NSCLC had been considered undruggable in past decades. This research sought to address a significant challenge in treating NSCLC with KRAS mutations, which are notoriously difficult to target effectively. Here, we proposal that the combined use of anlotinib and trametinib combined with tislelizumab may form an effective strategy for the treatment of KRAS-mutant NSCLC patients.

NCT ID: NCT06202599 Completed - Soft Tissue Sarcoma Clinical Trials

Fruquintinib-based Treatment for Refractory Bone and Soft Tissue Sarcomas After Several Lines of TKIs' Resistance

Start date: November 25, 2021
Phase:
Study type: Observational

This multicenter retrospective study assessed the efficacy and safety of fruquintinib-based treatment in patients with refractory bone and soft tissue sarcomas after several lines of TKIs' resistance.

NCT ID: NCT06098651 Recruiting - Solid Tumor, Adult Clinical Trials

A Study of DCR-STAT3 in Adults With Solid Tumors

Start date: August 14, 2023
Phase: Phase 1
Study type: Interventional

This is a sequential, ascending-dose, multicenter study conducted in patients with refractory solid tumors designed to evaluate the safety, tolerability, and pharmacokinetics of DCR-STAT3.

NCT ID: NCT06047860 Recruiting - Clinical trials for Advanced Solid Tumor

A Clinical Study of Recombinant Human Vascular Endothelial Inhibitor in Combination With PRaG for Advanced Refractory Non-small Cell Lung Cancer

Start date: June 16, 2023
Phase: Phase 2
Study type: Interventional

Exploring the efficacy and safety of recombinant human vascular endothelial inhibitor (Endo) in combination with Bragg therapy in advanced refractory non-small cell lung

NCT ID: NCT05790447 Recruiting - Clinical trials for Advanced Solid Tumor

Thymalfasin-based PRaG Mode for Advanced Refractory Solid Tumors

Start date: April 1, 2023
Phase: Phase 2
Study type: Interventional

This is an open-label, single-arm, Phase II investigator-initiated trial of precise thymalfasin-regulated therapy combined with hypofractionated radiotherapy, PD-1/PD-L1 inhibitor sequential GM-CSF for treatment of advanced refractory solid tumors.

NCT ID: NCT05767684 Recruiting - Solid Tumor Clinical Trials

Neoantigen Derived DCs as Cancer Treatment

Start date: June 1, 2023
Phase: Phase 1
Study type: Interventional

Tumor lysate or carcinoembryonic antigen (CEA) derived DCs-based therapy is safe and can elicites remarkable T-cell responses but mostly did not really transfer into significant clinical benefit. One possible reason is the lack of effective antigen and the immunosuppressive microenvironment. Now we are exploring another new strategy, prediction of neoantigen for priming DCs as cell-based therapy with or without booster of anti-VEGF/anti-PD-1.

NCT ID: NCT05752552 Recruiting - Lung Cancer Clinical Trials

Study to Determine the Safety and Pharmacokinetics of DO-2 in Patients With Advanced or Refractory Solid Tumours

Start date: December 20, 2022
Phase: Phase 1
Study type: Interventional

This study is a first-in-human, open-label, 2-part, Phase 1 dose escalation study of DO-2, administered orally to patients with advanced or refractory solid tumours, with MET aberrations, and no available, approved therapeutic alternative.

NCT ID: NCT05099549 Terminated - Clinical trials for Carcinoma, Non-Small-Cell Lung

Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers

Start date: November 3, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This is an open-label, multi-center study to evaluate the safety, tolerability, and anti-tumor activity of SNK01 in combination with AFM24 in subjects with advanced or metastatic EGFR-expressing cancers.

NCT ID: NCT04900519 Recruiting - Solid Tumor Clinical Trials

Study of the Safety and Efficacy of STI-6643 in Subjects With Advanced Solid Tumors

Start date: November 24, 2021
Phase: Phase 1
Study type: Interventional

This is a first-in-human, phase 1, open-label, dose-escalation study of STI-6643 administered by intravenous infusion in subjects with a relapsed/refractory advanced solid tumor.

NCT ID: NCT04809012 Withdrawn - Solid Tumor Clinical Trials

Study of STI-3031 in Patients With Selected Relapsed or Refractory Solid Tumors

Start date: June 2021
Phase: Phase 2
Study type: Interventional

This study evaluates the efficacy of STI-3031, an anti-PD-L1 antibody, in previously treated patients with selected solid tumors.